Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein

EMBO Reports

Volumn 8, Issue 12, 2007, Pages 1155-1161

  Usui, Ryosuke ^a   Shibuya, Masabumi ^b   Ishibashi, Shun ^c   Maru, Yoshiro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; MACROPHAGE MIGRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; UBIQUITINATION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; ENDOCYTOSIS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOPRECIPITATION; LIGANDS; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, LDL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 36749103151     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/sj.embor.7401103     Document Type: Article

References (23)

1. Baigent C et al, Cholesterol Treatment Trialists' (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278
2. Berliner JA, Territo M, Navab M, Andalibi A, Parhami F, Liao F, Kim J, Estworthy S, Lusis AJ, Fogelman AM (1992) Minimally modified lipoproteins in diabetes, Diabetes 41(Suppl 2): 74-76
3. Brown MS, Goldstein JL (1986) A receptor-mediated passway for cholesterol homeostasis. Science 232: 34-47
4. Crouse JR, Parks JS, Schey HM, Kahl FR (1985) Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 26: 566-574
5. Cunningham SA, Arrate MP, Brock TA, Waxham MN (11997) Interactions of FLT-1 and KDR with phospholipase Cγ: Identification of the phosphotyrosine binding sites. Biochem Biophys Res Commun 240 635-639
6. Garuti R, Jones C, Li WP, Michaely P, Herz J, Gerard RD, Cohen JC, Hobbs HH (2005) The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem 280: 40996-41004
7. Goldstein JL, Basu SK, Brown MS (1983) Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 98 241-260
8. Hara S, Nagano Y, Sasada M, Kita T (1992) Probucol pretreatment enhances the chemotaxis of mouse peritoneal macrophages. Arterioscler Thromb 12: 593-600
9. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95: 9349-9354
10. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK (1994) Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 93: 1885-1893
11. Ito N, Wernstedt C, Engstrom U, Claesson-Welsh L (11998) Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation, sites and binding of SH2 domain-containing molecules. J Biol Chem 273: 23410-23418
12. Kobayashi S, Sawano A, Nojima Y, Shibuya M, Maru Y (2004) the c-Cbl/ CD2AP complex regulates VEGF-induced en'docytosis and degradation of Flt-1 (VEGFR-1). FASEB J 18: 929-931
13. Lerdrup M, Hommelgaard AM, Grandal M, van Deurs B (2006) Geldanamycin stimulates internalization of ErbB2 in a proteasome- dependent way. J Cell Sci 119: 85-95
14. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B (2002) Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8: 831-840
15. Mary TC, Jing W, Donald JF (2002) Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem 3: 32
16. Matsumoto Y, Tanaka K, Hirata G, Hanada M, Matsuda S, Shuto T, Iwamoto Y (2002) Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol 168: 5824-5831
17. Michaely P, Zhao Z, Wei-Ping Li, Garuti R, Huang LJ, Hobbs HH, Cohen JC (2007) Identification of a VLDL-induced, FDNPVY-independent internalization mechanism for the LDLR. EMBO J 26: 3273-3282
18. Moore KJ, Freeman MW (2006) Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 26: 1702-1711
19. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J (2001) Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 100: 4736-4741
20. Okamoto A, Iwamoto Y, Maru Y (2006) Oxidative stress-responsive transcription factor ATF3 potentially mediates diabetic angiopathy. Mol Cell Biol 26: 1087-1097
21. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC (2001) Receptor heterodimerization: Essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 21: 6387-6394
22. Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39: 469-478
23. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924